A Phase 3 interventional study of AGN-151586 in Glabellar Lines, sponsored by AbbVie. Completed at 43 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-25.
Sponsored by AbbVie · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Facial lines that develop from repeated facial expression, such as glabellar lines (GL), are typically treated by selectively weakening specific muscles with botulinum toxin. The primary purpose of this study is to evaluate the safety of AGN-151586 over up to three treatments of the study drug to improve the appearance of glabellar lines.
AGN-151586 is an investigational product being developed for the treatment of GL. Around 940 to 1100 adult participants with moderate to severe GL will be enrolled in the study in approximately 45 sites in the United States.
This is an open-label study in which all participants will receive 5 intramuscular AGN-151586 injections to the glabellar complex on Day 1. Participants meeting retreatment criteria may receive up to 2 additional doses of treatment during the study.
Participants will attend regular visits during the study at a study site. The effect of the treatment will be checked by medical assessments, blood tests, telephone calls, questionnaires and checking for side effects.
AbbVie is the lead sponsor of 977 studies on the registry; 135 are open to participants now.
Of its 359 completed or terminated interventional studies of FDA-regulated products, 215 (60%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Presence or history of any medical condition that may place the subject at increased risk following exposure to AGN-151586 or interfere with the study evaluation, including:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive 5 intramuscular injections in the glabellar complex on Day 1 (Dose 1). Based on meeting the retreatment criteria, the participant may receive up to 2 additional doses of open-label treatments.
Drug: AGN-151586
Powder for Solution for Intramuscular Injection
Number of Participants With Adverse Events
An adverse event (AE) is defined as any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product which does not necessarily have a causal relationship with the treatment. The investigator assesses the relationship of each event to the use of study drug.
Time frame: Day 1 (Baseline) to Day 126
Participants With Post-Baseline Potentially Clinically Important (PCI) Values for Systolic Blood Pressure
The number of subjects with at least 1 PCI post-baseline value during the study are reported. A post-baseline value was considered PCI if it met both the observed-value and the change-from-baseline criteria.
Time frame: Day 1 (Baseline) to Day 126
Participants With Post-Baseline PCI Values for Diastolic Blood Pressure
The number of subjects with at least 1 PCI post-baseline value during the study are reported. A post-baseline value was considered PCI if it met both the observed-value and the change-from-baseline criteria.
Time frame: Day 1 (Baseline) to Day 126
Participants With Post-Baseline PCI Values for Heart Rate
The number of subjects with at least 1 PCI post-baseline value during the study are reported. A post-baseline value was considered PCI if it met both the observed-value and the change-from-baseline criteria.
Time frame: Day 1 (Baseline) to Day 126
Participants With Post-baseline PCI Values in Temperature
Only the observed-value criterion (\>= 38.3 C) was needed for temperature to be potentially clinically important (but must be more extreme than baseline, if baseline was present).
Time frame: Day 1 (Baseline) to Day 126
Participants With Post-baseline PCI Values in Electrocardiogram Parameters
12-lead resting ECGs will be recorded. Parameters include heart rate, PR interval, QT interval, QRS duration, and QT interval corrected using Fridericia's formula (QTcF). A post-baseline value is considered potentially clinically important if it meets either the observed-value or the change-from-baseline criteria (but must be more extreme than baseline if baseline is present).
Time frame: Day 1 (Baseline) to Day 126
Presence of Binding and Neutralizing Antidrug Antibodies to AGN-151586
Blood samples for immunogenicity testing were collected from participants treated with AGN-151586 at predetermined timepoints. Collected samples were processed to yield serum for detection of binding and neutralizing antibodies to AGN-151586.
Time frame: Day 1 (Baseline) to Day 126
A total of 992 participants (ITT population) were enrolled at 41 sites in the USA and Puerto Rico. A total of 985 participants received at least 1 dose of AGN-151586; 916 participants received at least 2 doses, and 846 participants received 3 doses. The safety population included 985 participants who received at least one dose of AGN-151586.
| Milestone | All Enrolled Participants (ITT) | AGN-151586 (Dose 1) | AGN-151586 (Dose 2) | AGN-151586 (Dose 3) |
|---|---|---|---|---|
| Started | 992 | 0 | 0 | 0 |
| Completed | 985 | 0 | 0 | 0 |
| Not completed | 7 | 0 | 0 | 0 |
| Withdrew: Lost to follow-up | 2 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 4 | 0 | 0 | 0 |
| Withdrew: Other, not specified | 1 | 0 | 0 | 0 |
| Milestone | All Enrolled Participants (ITT) | AGN-151586 (Dose 1) | AGN-151586 (Dose 2) | AGN-151586 (Dose 3) |
|---|---|---|---|---|
| Started | 0 | 985 | 0 | 0 |
| Completed | 0 | 916 | 0 | 0 |
| Not completed | 0 | 69 | 0 | 0 |
| Withdrew: Lost to follow-up | 0 | 11 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 35 | 0 | 0 |
| Withdrew: Withdrawal by subject due to adverse event | 0 | 4 | 0 | 0 |
| Withdrew: Covid-19 infection | 0 | 1 | 0 | 0 |
| Withdrew: Other, not specified | 0 | 18 | 0 | 0 |
| Milestone | All Enrolled Participants (ITT) | AGN-151586 (Dose 1) | AGN-151586 (Dose 2) | AGN-151586 (Dose 3) |
|---|---|---|---|---|
| Started | 0 | 0 | 916 | 0 |
| Completed | 0 | 0 | 848 | 0 |
| Not completed | 0 | 0 | 68 | 0 |
| Withdrew: Lost to follow-up | 0 | 0 | 14 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 29 | 0 |
| Withdrew: Withdrawal by subject due to adverse event | 0 | 0 | 4 | 0 |
| Withdrew: Covid-19 infection | 0 | 0 | 1 | 0 |
| Withdrew: Other, not specified | 0 | 0 | 20 | 0 |
| Milestone | All Enrolled Participants (ITT) | AGN-151586 (Dose 1) | AGN-151586 (Dose 2) | AGN-151586 (Dose 3) |
|---|---|---|---|---|
| Started | 0 | 0 | 0 | 846 |
| Completed | 0 | 0 | 0 | 836 |
| Not completed | 0 | 0 | 0 | 10 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 7 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 3 |
An adverse event (AE) is defined as any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product which does not necessarily have a causal relationship with the treatment. The investigator assesses the relationship of each event to the use of study drug.
| Participants | AGN-151586 (Dose 1) | AGN-151586 (Dose 2) | AGN-151586 (Dose 3) | Any AGN-151586 |
|---|---|---|---|---|
| Number of Participants With Adverse Events | 213 | 174 | 128 | 374 |
The number of subjects with at least 1 PCI post-baseline value during the study are reported. A post-baseline value was considered PCI if it met both the observed-value and the change-from-baseline criteria.
| participants | AGN-151586 (Dose 1) | AGN-151586 (Dose 2) | AGN-151586 (Dose 3) | Any AGN-151586 |
|---|---|---|---|---|
| >= 160 mmHg and Increase of >=20 mmHg | 5 | 6 | 14 | 19 |
| <= 90 mmHg and Decrease of >= 20 mmHg | 1 | 3 | 6 | 10 |
The number of subjects with at least 1 PCI post-baseline value during the study are reported. A post-baseline value was considered PCI if it met both the observed-value and the change-from-baseline criteria.
| participants | AGN-151586 (Dose 1) | AGN-151586 (Dose 2) | AGN-151586 (Dose 3) | Any AGN-151586 |
|---|---|---|---|---|
| >= 100 mmHg and Increase of >= 15 mmHg | 3 | 6 | 9 | 16 |
| <= 50 mmHg and Decrease of >= 15 mmHg | 1 | 3 | 1 | 5 |
The number of subjects with at least 1 PCI post-baseline value during the study are reported. A post-baseline value was considered PCI if it met both the observed-value and the change-from-baseline criteria.
| participants | AGN-151586 (Dose 1) | AGN-151586 (Dose 2) | AGN-151586 (Dose 3) | Any AGN-151586 |
|---|---|---|---|---|
| >= 110 beats/minute and Increase of >= 15 beats/minute | 4 | 5 | 4 | 10 |
| <= 50 beats/minute and Decrease of >= 15 beats/minute | 3 | 3 | 7 | 8 |
Only the observed-value criterion (\>= 38.3 C) was needed for temperature to be potentially clinically important (but must be more extreme than baseline, if baseline was present).
| Participants | AGN-151586 (Dose 1) | AGN-151586 (Dose 2) | AGN-151586 (Dose 3) | Any AGN-151586 |
|---|---|---|---|---|
| Participants With Post-baseline PCI Values in Temperature | 0 | 0 | 0 | 0 |
12-lead resting ECGs will be recorded. Parameters include heart rate, PR interval, QT interval, QRS duration, and QT interval corrected using Fridericia's formula (QTcF). A post-baseline value is considered potentially clinically important if it meets either the observed-value or the change-from-baseline criteria (but must be more extreme than baseline if baseline is present).
| participants | AGN-151586 (Dose 1) | AGN-151586 (Dose 2) | AGN-151586 (Dose 3) | Any AGN-151586 |
|---|---|---|---|---|
| QRS Interval >= 150 msec | 1 | 1 | 1 | 1 |
| PR Interval >= 250 msec | 1 | 0 | 1 | 1 |
| QTcB > 500 msec or Increase of > 60 msec | 3 | 2 | 3 | 8 |
| QTcF > 500 msec or Increase of > 60 msec | 0 | 0 | 0 | 0 |
Blood samples for immunogenicity testing were collected from participants treated with AGN-151586 at predetermined timepoints. Collected samples were processed to yield serum for detection of binding and neutralizing antibodies to AGN-151586.
| participants | AGN-151586 (1 Dose) | AGN-151586 (2 Doses) | AGN-151586 (3 Doses) | Any AGN-151586 |
|---|---|---|---|---|
| Binding Antibodies (AGN-151586) | 0 | 0 | 2 | 2 |
| Neutralizing Antibodies (AGN-151586) | — | — | 1 | 1 |
Collected over All-cause mortality and adverse event tables include events reported from enrollment to end of study. Of the 992 participants enrolled, 7 did not receive treatment and were discontinued during the screening period. The median time participants were followed was 12.0 days for the untreated group; 57.0 days for the AGN-151586 (1 Dose) group; 101.0 days for the AGN-151586 (2 Doses) group; and 138.0 days for the AGN-151586 (3 Doses) group.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Not Treated | 0/7 (0%) | 0/7 (0%) | 0/7 (0%) |
| AGN-151586 (1 Dose) | 0/69 (0%) | 3/69 (4.3%) | 11/69 (15.9%) |
| AGN-151586 (2 Doses) | 0/70 (0%) | 0/70 (0%) | 9/70 (12.9%) |
| AGN-151586 (3 Doses) | 0/846 (0%) | 4/846 (0.5%) | 147/846 (17.4%) |
| Event | Not Treated | AGN-151586 (1 Dose) | AGN-151586 (2 Doses) | AGN-151586 (3 Doses) |
|---|---|---|---|---|
| BILIARY DILATATIONHepatobiliary disorders | 0/7 | 1/69 | 0/70 | 0/846 |
| CHOLECYSTITIS ACUTEHepatobiliary disorders | 0/7 | 1/69 | 0/70 | 0/846 |
| DEVICE RELATED INFECTIONInfections and infestations | 0/7 | 1/69 | 0/70 | 0/846 |
| JAW FRACTUREInjury, poisoning and procedural complications | 0/7 | 1/69 | 0/70 | 0/846 |
| RIB FRACTUREInjury, poisoning and procedural complications | 0/7 | 1/69 | 0/70 | 0/846 |
| ROAD TRAFFIC ACCIDENTInjury, poisoning and procedural complications | 0/7 | 1/69 | 0/70 | 0/846 |
| SKIN LACERATIONInjury, poisoning and procedural complications | 0/7 | 1/69 | 0/70 | 0/846 |
| SPINAL COLUMN INJURYInjury, poisoning and procedural complications | 0/7 | 1/69 | 0/70 | 0/846 |
| OBSTRUCTIVE PANCREATITISGastrointestinal disorders | 0/7 | 0/69 | 0/70 | 1/846 |
| CHOLELITHIASISHepatobiliary disorders | 0/7 | 0/69 | 0/70 | 1/846 |
| Event | Not Treated | AGN-151586 (1 Dose) | AGN-151586 (2 Doses) | AGN-151586 (3 Doses) |
|---|---|---|---|---|
| HEADACHENervous system disorders | 0/7 | 4/69 | 6/70 | 77/846 |
| INJECTION SITE PAINGeneral disorders | 0/7 | 4/69 | 1/70 | 44/846 |
| COVID-19Infections and infestations | 0/7 | 3/69 | 2/70 | 46/846 |
Baseline analyses were performed on the ITT Population, consisting of all enrolled subjects (N=992).
| Age, Categorical(Participants) | AGN-151586 |
|---|---|
| <=18 years | 0 |
| Between 18 and 65 years | 899 |
| >=65 years | 93 |
| Age, Continuous(Years) | AGN-151586 |
|---|---|
| Mean | 49.3 ± 11.52 |
| Sex: Female, Male(Participants) | AGN-151586 |
|---|---|
| Female | 852 |
| Male | 140 |
| Ethnicity (NIH/OMB)(Participants) | AGN-151586 |
|---|---|
| Hispanic or Latino | 238 |
| Not Hispanic or Latino | 754 |
| Unknown or Not Reported | 0 |
| Race (NIH/OMB)(Participants) | AGN-151586 |
|---|---|
| American Indian or Alaska Native | 16 |
| Asian | 22 |
| Native Hawaiian or Other Pacific Islander | 2 |
| Black or African American | 65 |
| White | 876 |
| More than one race | 11 |
| Unknown or Not Reported | 0 |
| Region of Enrollment(participants) | AGN-151586 |
|---|---|
| Puerto Rico | 43 |
| United States | 949 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols, analyses plans, clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: For details on when studies are available for sharing visit https://vivli.org/ourmember/abbvie/
Access criteria: Access to this clinical trial data can be requested by any qualified researchers who engage in rigorous independent scientific research, and will be provided following review and approval of a research proposal and statistical analysis plan and execution of a data sharing statement. Data requests can be submitted at any time after approval in the US and/or EU and a primary manuscript is accepted for publication. For more information on the process, or to submit a request, visit the following link https://www.abbvieclinicaltrials.com/hcp/data-sharing/
Data sharing details ↗ · vivli.org
Ran from Feb 2022 to primary completion in Jun 2023, 16 months.
Results were first posted in Sep 2026, 3 years 2 months after primary completion. A results delay was requested in May 2024.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: trenibotulinumtoxinE